Open AccessPossible Role of Ivermectin Mucoadhesive Nanosuspension Nasal Spray in Recovery of Post-COVID-19 Anosmia
Author(s) -
Zaki F. Aref,
Shamardan Ezzeldin S. Bazeed,
Mohammed H. Hassan,
Abeer S. Hassan,
Ali A. Ghweil,
Mennatallah Ali Abdelrhman Sayed,
Alaa Rashad,
Haggagy Mansour,
Aida A. Abdelmaksoud
Publication year - 2022
Publication title -
infection and drug resistance
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.033
H-Index - 39
ISSN - 1178-6973
DOI - 10.2147/idr.s381715
Subject(s) - anosmia , ivermectin , placebo , medicine , nasal spray , nasal administration , anesthesia , saline , covid-19 , surgery , pharmacology , veterinary medicine , pathology , alternative medicine , disease , infectious disease (medical specialty)
Anosmia or hyposmia, with or without taste changes, are common symptoms that occur in SARS-CoV-2 infection and frequently persist as post-COVID-19 manifestations. This is the first trial to assess the potential value of using local ivermectin in the form of a mucoadhesive nanosuspension nasal spray to treat post-COVID-19 anosmia.